Cardiac myofibroblasts: A novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 3, 2003, Pages 277-286

  Chintalgattu, Vishnu ^a   Nair, Devi M ^a   Katwa, Laxmansa C ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Angiotensin II; Cardiac myofibroblasts; Myocardial infarction; VEGF

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ISOPROTEIN; MESSENGER RNA; PRIMER DNA; RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CELL ISOLATION; CONTROLLED STUDY; HEART CELL CULTURE; HEART INFARCTION; HEART MUSCLE CELL; HYBRIDIZATION; MALE; MYOFIBROBLAST; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RAT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; UPREGULATION; WESTERN BLOTTING;

EID: 0037350079     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2828(03)00006-3     Document Type: Article

References (39)

1. Komuro T. Re-evaluation of fibroblasts and fibroblast-like cells. Anat Embryol. 182:1990;103-112.
2. Sappino A.P., Schurch W., Gabbiani G. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest. 63:1990;144-161.
3. Fries K.M., Blieden T., Looney R.J., Sempowski G.D., Silvera M.R., Willis R.A., et al. Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin Immunol Immunopathol. 72:1994;283-292.
4. Schmitt-Graff A., Desmouliere A., Gabbiani G. Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity. Virchows Arch. 425:1994;3-24.
5. Katwa L.C., Campbell S.E., Tyagi S.C., Lee S.J., Cicila G.T., Weber K.T. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol. 29:1997;1375-1386.
6. Powell D.W., Mifflin R.C., Valentich J.D., Crowe S.E., Saada J.I., West A.B. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol. 277:1999;C1-9.
7. Campbell S.E., Katwa L.C. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 29:1997;1947-1958.
8. Weber K.T., Sun Y., Katwa L.C. Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Int J Biochem Cell Biol. 29:1997;31-42.
9. Katwa L.C. Role of endothelins in cardiovascular disease. Gupta S.K. Pharmacology and therapeutics in the new millennium. 2001;25-36 Narosa Publishing House, New Delhi, India.
10. Tzanidis A., Lim S., Hannan R.D., See F., Ugoni A.M., Krum H. Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta. J Mol Cell Cardiol. 1:(33):2001;969-981.
11. Staufenberger S., Jacobs M., Brandstatter K., Hafner M., Regitz-Zagrosek V., Ertl G., et al. Angiotensin II type 1-receptor regulation and differential trophic effects on rat cardiac myofibroblasts after acute myocardial infarction. J Cell Physiol. 187:2001;326-335.
12. Breier G., Albrecht U., Sterrer S., Risau W. Expression of vascularendothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development. 114:1992;521-532.
13. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 72:1993;835-846.
14. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:1996;435-439.
15. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:1996;439-442.
16. Frank S., Hubner G., Breier G., Longaker M.T., Greenhalgh D.G., Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem. 270:1995;12607-12613.
17. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 359:1992;845-848.
18. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 367:1994;576-579.
19. Alon T., Hemo I., Itin A., Pe'er J., Stone J., Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat M. 1:1995;1024-1028.
20. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., Jain R.K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA. 93:1996;14765-14770.
21. Ferrara N., Davis-Smith T. The biology of vascular endothelial growth factor. Endocr Rev. 18:1997;4-25.
22. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., et al. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 273:1998;30336-30343.
23. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 103:1999;159-165.
24. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 280:2001;C1358-1366.
25. Olofsson B., Pajusola K., Kaipainen A., von Euler G., Joukov V., Saksela O., et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA. 93:1996;2576-2581.
26. Shalaby F., Ho J., Stanford W.L., Fisher K.D., Schuh A.C., Schartz L., et al. A requirement for Flk-1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 89:1997;981-990.
27. Chua C.C., Hamdy R.C., Chua B.H. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta. 1401:1998;187-194.
28. Otani A., Takagi H., Suzuma K., Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res. 82:1998;619-628.
29. Roy S.G., Nozaki Y., Phan S.H. Regulation of alpha-smooth muscle actin gene expression in myofibroblast differentiation from rat lung fibroblasts. Int J Biochem Cell Biol. 33:2001;723-734.
30. Bausero P., Ben-Mahdi M., Mazucatelli J., Bloy C., Perrot-Applanat M. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am J Physiol Heart Circ Physiol. 279:2000;H2033-2042.
31. DiSalvo J., Bayne M.L., Conn G., Kwok P.W., Trivedi P.G., Soderman D.D., et al. Purification and characterization of a naturally occurring vascular endothelial growth factor-placenta growth factor heterodimer. J Biol Chem. 270:1995;7717-7723.
32. Chen H., Treweeke A.T., West D.C., Till K.J., Cawley J.C., Zuzel M., et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood. 96:2000;3181-3187.
33. Yamane A., Seetharam L., Yamaguchi S., Gotoh N., Takahashi T., Neufeld G., et al. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene. 9:1994;2683-2690.
34. Wen Y., Edelman J.L., Kang T., Zeng N., Sachs G. Two functional forms of vascular endothelial growth factor receptor-2/Flk-1 mRNA are expressed in normal rat retina. J Biol Chem. 273:1998;2090-2097.
35. Zachary I., Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 49:2001;568-581.
36. Tamarat R., Silvestre J.S., Kubis N., Benessiano J., Duriez M., deGasparo M., et al. Endothelial nitric oxide synthase lies downstream from angiotensin II-induced angiogenesis in ischemic hind limb. Hypertension. 39:2002;830-835.
37. Weber K.T., Sun Y., Katwa L.C., Cluetjens J.P. Tissue repair and angiotensin II generated at sites of healing. Basic Res Cardiol. 92:1997;75-78.
38. Sun Y., Weber K.T. Fibrosis and myocardial ACE: possible substrate and independence from circulating angiotensin II. J Card Fail. 1:1994;81-89.
39. Gruden G., Thomas S., Burt D., Zhou W., Chusney G., Gnudi L., et al. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol. 10:1999;730-737.